Dexpramipexoles failure was the first prominent booboo under George Scangos, who moved into the CEO position in. 하지만 회사는 이를 털어내고 계속 나아갈 것입니다. The next significant drug to watch coming down the pipes is BG, an oral treatment for early stage MS.